Background. The intragastric balloon (IB) system has been designed to assist weight loss by partially filling the stomach and inducing satiety. It is indicated for temporary use in order to obtain weight loss in seriously obese patients with BMI > 40 or averaging 30–35 with comorbidities. In such patients previous controlled diet programs failed to achieve and maintain weight loss. The aim of this study was to evaluate the weight decrease induced by IB placement. Methods. Thirty patients were admitted to the study (age: 22–64 years; 11 males). The patients weight ranged 90–180 and BMI ranged 30– 57. Respiratory disorders affected two patients; one was scheduled for a cardiac transplant due to cardiomyopathy, and 1 had no appreciable results from previous surgical banding. The remaining patients were affected by pathological obesity with failure of controlled diet programs. Bioenterics Intragastric Balloon System (INAMED Co., S. Barbara, CA, USA) has been placed in the stomach by means of endoscopy and was filled with saline (400–500 ml). The maximum placement period was 6 months. The efficacy of the treatment was evaluated calculating the difference of BMI values before and after IB insertion. Results. In three patients the IB was removed for intolerance (continuous vomiting and epigastralgia) 2 months later and in one patient after 2 days. The mean value of BMI decrease was 4.4 kg/m2 in 26 patients (see Table 1). Complications, even including the above-mentioned intolerance, were observed in 33% of the patients: oesophagitis (5); erosive gastritis (1); gastric ulcer. Conclusions. Our study demonstrated that a significant weight loss can be achieved with the use of IB without serious complications. Therefore, IB adoption for the treatment of obesity could be considered useful and safe as well
UTILITY AND EFFICACY OF BIOENTERICS GASTRIC BALLOON IN MORBID OBESITY
RICCI, Giorgio;ALVISI, Vittorio
2004
Abstract
Background. The intragastric balloon (IB) system has been designed to assist weight loss by partially filling the stomach and inducing satiety. It is indicated for temporary use in order to obtain weight loss in seriously obese patients with BMI > 40 or averaging 30–35 with comorbidities. In such patients previous controlled diet programs failed to achieve and maintain weight loss. The aim of this study was to evaluate the weight decrease induced by IB placement. Methods. Thirty patients were admitted to the study (age: 22–64 years; 11 males). The patients weight ranged 90–180 and BMI ranged 30– 57. Respiratory disorders affected two patients; one was scheduled for a cardiac transplant due to cardiomyopathy, and 1 had no appreciable results from previous surgical banding. The remaining patients were affected by pathological obesity with failure of controlled diet programs. Bioenterics Intragastric Balloon System (INAMED Co., S. Barbara, CA, USA) has been placed in the stomach by means of endoscopy and was filled with saline (400–500 ml). The maximum placement period was 6 months. The efficacy of the treatment was evaluated calculating the difference of BMI values before and after IB insertion. Results. In three patients the IB was removed for intolerance (continuous vomiting and epigastralgia) 2 months later and in one patient after 2 days. The mean value of BMI decrease was 4.4 kg/m2 in 26 patients (see Table 1). Complications, even including the above-mentioned intolerance, were observed in 33% of the patients: oesophagitis (5); erosive gastritis (1); gastric ulcer. Conclusions. Our study demonstrated that a significant weight loss can be achieved with the use of IB without serious complications. Therefore, IB adoption for the treatment of obesity could be considered useful and safe as wellI documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
